Healthcare Equipment and Supplies
Company Overview of iRhythm Technologies, Inc.
iRhythm Technologies, Inc. provides cardiac rhythm monitoring devices for physicians, clinical staff, and patients. It offers products for patients suffering from abnormal heart rhythm or arrhythmia. The company’s products include Zio Continuous Card, a prescription-only single use continuously recording ECG monitor for use on patients who suffer from transient symptoms, such as syncope, palpitations, shortness of breath, dizziness, fatigue, or anxiety; Zio Event Card, a prescription-only single-use disposable and looping ECG monitor for use on patients with transient symptoms, such as syncope, palpitations, shortness of breath, or dizziness; and recycled Zio devices for plastic cases, PCB b...
650 Townsend Street
San Francisco, CA 94103
Founded in 2006
Key Executives for iRhythm Technologies, Inc.
Chief Clinical Officer and Executive Vice President
Executive Vice President of Corporate Sales & Payer Relations
Executive Vice President of Research & Development
Compensation as of Fiscal Year 2014.
iRhythm Technologies, Inc. Key Developments
iRhythm Appoints Tiba Aynechi, PhD to the Board of Directors
May 22 14
iRhythm Technologies, Inc. announced that it closed a $17 million Series E financing led by Novo A/S. Norwest Venture Partners, which led the company's Series D financing, also participated in the oversubscribed round. The company also announced that Tiba Aynechi, PhD principal at Novo Ventures (US) Inc., has joined the company's board of directors. Dr. Aynechi has more than 10 years of combined research, banking, and venture capital experience in life sciences that spans various therapeutic areas and technology platforms.
iRhythm Technologies, Inc. Announces Publication of Zio(R) Patch Study Demonstrating Superior Ability to Detect Atrial Fibrillation
Mar 7 13
iRhythm Technologies, Inc. announced clinical study findings showing that use of the Zio(R) Patch resulted in a change in treatment strategy for nearly one-third of patients with paroxysmal atrial fibrillation (AF). The data, which will be published in Pacing and Clinical Electrophysiology (PACE) Journal on March 12, showed that the Zio Patch ambulatory cardiac monitoring system demonstrated improved clinical accuracy and detection of potentially malignant arrhythmias in AF patients compared with a 24-hour Holter Monitor in the same patients. The self-controlled study, conducted by Dr. Michael A. Rosenberg, Dr. Peter J. Zimetbaum and colleagues at Beth Israel Deaconess Medical Center's Division of Electrophysiology in Boston, compared iRhythm's Zio Patch to a 24-hour Holter monitor in 74 patients with AF who were referred for monitoring to detect and characterize their arrhythmias. Study Results: Overall, the study results showed that the Zio Patch was superior to a 24-hour monitor in detecting AF episodes and comparable in quantifying AF burden. Specifically, the Zio Patch identified AF episodes in 35% of patients who were found to have no AF by the Holter monitor. The Zio Patch also provided the additional benefit of detecting other more malignant arrhythmias due to the longer duration of detection. These benefits led to clinically meaningful changes in the existing treatment plans for 21 of the study patients (28.4% of study participants).
Similar Private Companies By Industry
Recent Private Companies Transactions
May 16, 2014